Systemic Bio
The business, the turning points, and the decisions behind them.
01 / WHAT IT BUILT
What the company did
Systemic Bio, a 3D Systems subsidiary, produced bioprinted tissue and organ-on-chip models for pharmaceutical drug discovery and testing.
02 / Systemic Bio FAILURE REASONS
Failure reasons
CEO Taci Pereira explained that the project required substantial investment, while parent company 3D Systems was concentrating on profitability and could no longer fund that cost-intensive development. The disclosed reason concerns continued corporate backing, not proof that its tissue platform had technically failed.
03 / EVENT HISTORY
Events in the structured record
- Subsidiary launched
3D Systems launched the bioprinting subsidiary in September.
- Development and closure
By July the business had developed h-VIOS and manufacturing capacity for vascularized hydrogels. July reporting confirmed a closure decision earlier that month.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN
How the factors connect
- 01
Bioprinting development required substantial continued investment
- 02
Parent company prioritized profitability
- 03
Parent could not maintain the cost-intensive project
- 04
Subsidiary closed